Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

TGTX

TG THERAPEUTICS, INC.

Pharmaceutical Preparations · SIC 2834CIK 1001316Held by 2 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
$616.0M
Net Income FY2025
$447.0M
EPS (Basic, as reported)
$3.10
Net Margin FY2025
72.6%
ROE FY2025
69.0%
Total Equity
$648.0M
Shares Out
153M
Business description

TG THERAPEUTICS, INC. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2011–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itRevenue: 0 → 616
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue0000073234329616
Cost of revenue—————(1)0(14)(38)(101)
Research & development(69)(103)(159)(154)(166)(223)(125)(76)(94)(160)
Selling, general & administrative———(15)(108)(128)(70)(123)(154)(232)
General & administrative(10)(16)(15)(15)(108)—————
Total operating expenses(79)(119)(175)(169)(274)(351)(196)(213)(287)(493)
Operating income(79)(119)(174)(169)(274)(345)(193)2142123
Interest expense—(1)(1)(5)(6)(6)(10)(13)(24)(27)
Other income (expense), net101(4)(6)(3)(5)(8)(16)(16)
Pre-tax income(78)(118)(173)00(348)(198)1326107
Income tax expense00000000(2)(340)
Net income(78)(118)(173)(173)(279)(348)(198)1323447
EPS — basic————($2.42)($2.63)($1.46)$0.09$0.16$3.10
EPS — diluted————($2.42)($2.63)($1.46)$0.09$0.15$2.77
Shares outstanding — basic (M)————115132135142145144
Shares outstanding — diluted (M)————115132135149160161

Showing the latest 10 of 15 fiscal years.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.